This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (81)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Medical Ethics  • Statistics and Research Methods  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Case Study

Elizabeth A. Boyd, PhD; Lisa A. Bero, PhD

JAMA. 2000;284:2209-2214.

Context  A growing number of academic researchers receive industry funding for clinical and basic research, but little is known about the personal financial relationships of researchers with their industry sponsors.

Objectives  To assess the extent to which faculty researchers have personal financial relationships with the sponsors of their research, the nature of those financial relationships, and efforts made at the institutional level to address disclosed financial relationships and perceived conflicts of interest.

Design and Setting  Case study of the University of California, San Francisco (UCSF). Data sources included disclosure forms and official documents maintained by the UCSF Office of Research Administration from December 1980 to October 1999, including decisions made by the UCSF Chancellor's Advisory Panel on Relations with Industry.

Main Outcome Measures  Number and types of personal financial relationships with external sponsors (positive financial disclosures from all clinical, basic, or social science faculty who were principal investigators), amount of annual income received from sponsors, and decisions and management strategies used by the advisory panel.

Results  By 1999, almost 7.6% of faculty investigators reported personal financial ties with sponsors of their research. Throughout the study period, 34% of disclosed relationships involved paid speaking engagements (range, $250–$20,000 per year), 33% involved consulting agreements between researcher and sponsor (range, <$1000–$120,000 per year), and 32% involved the investigator holding a position on a scientific advisory board or board of directors. Fourteen percent involved equity ownership, and 12% involved multiple relationships. The advisory panel recommended managing perceived conflicts of interest in 26% of the cases, including recommending the sale of stock, refusing additional payment for talks, resigning from a management position, or naming a new principal investigator for a project.

Conclusions  Faculty researchers are increasingly involved in financial relationships with their research sponsors. Guidelines for what constitutes a conflict and how the conflict should be managed are needed if researchers are to have consistent standards of behavior among institutions.

Author Affiliations: Center for Health Care Evaluation, Health Services Research and Development Program, Department of Veterans Affairs, Palo Alto, Calif (Dr Boyd); Institute for Health Policy Studies, School of Medicine (Drs Boyd and Bero), and Department of Clinical Pharmacy, School of Pharmacy (Dr Bero), University of California, San Francisco. Dr Bero serves as chair of the Chancellor's Advisory Panel on Relations with Industry at the University of California, San Francisco, from September 1999 to present.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Financial Indigestion
Jerome P. Kassirer
JAMA. 2000;284(17):2156-2157.
EXTRACT | FULL TEXT  

Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 x 10⁶/L CD4 Cell Counts: A Randomized Controlled Trial
James O. Kahn, Deborah Weng Cherng, Kenneth Mayer, Henry Murray, Stephen Lagakos, and for the 806 Investigator Team
JAMA. 2000;284(17):2193-2202.
ABSTRACT | FULL TEXT  

Policies on Faculty Conflicts of Interest at US Universities
Mildred K. Cho, Ryo Shohara, Anna Schissel, and Drummond Rennie
JAMA. 2000;284(17):2203-2208.
ABSTRACT | FULL TEXT  

Conflicts of Interest in Biomedical Research
David Korn
JAMA. 2000;284(17):2234-2237.
EXTRACT | FULL TEXT  

Conflict of Interest and the Public Trust
Catherine D. DeAngelis
JAMA. 2000;284(17):2237-2238.
EXTRACT | FULL TEXT  

November 1, 2000
JAMA. 2000;284(17):2257-2258.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

"But Doctors do it...": Nurses' Views of Gifts and Information from the Pharmaceutical Industry
Jutel and Menkes
The Annals of Pharmacotherapy 2009;43:1057-1063.
ABSTRACT | FULL TEXT  

Criteria for evaluating tobacco control research funding programs and their application to models that include financial support from the tobacco industry
Cohen et al.
Tobacco Control 2009;18:228-234.
FULL TEXT  

Shifts in guidelines for ethical scientific conduct: how public and private organizations create and change norms of research integrity.
Montgomery and Oliver
Social Studies of Science 2009;39:137-155.
ABSTRACT  

Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues
Timimi
Adv. Psychiatr. Treat. 2008;14:3-9.
ABSTRACT | FULL TEXT  

Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study
Yank et al.
BMJ 2007;335:1202-1205.
ABSTRACT | FULL TEXT  

A review of conflict of interest, competing interest, and bias for toxicologists
Claxton
Toxicol Ind Health 2007;23:557-571.
ABSTRACT  

Frequency, Type, and Monetary Value of Financial Conflicts of Interest in Cancer Clinical Research
Hampson et al.
JCO 2007;25:3609-3614.
ABSTRACT | FULL TEXT  

Financial Relationships between Institutional Review Board Members and Industry
Campbell et al.
NEJM 2006;355:2321-2329.
ABSTRACT | FULL TEXT  

The Limits of Disclosure: What Research Subjects Want to Know about Investigator Financial Interests
Grady et al.
J Law Med Ethics 2006;34:592-599.
 

Government, University and Industry Relations: The Case of Biotechnology in the Delhi Region
Sardana and Krishna
Science Technology Society 2006;11:351-378.
ABSTRACT  

Symposium. Relationships with Industry: Critical for New Technology or an Unnecessary Evil?
Jacobs et al.
JBJS 2006;88:1650-1663.
FULL TEXT  

Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products
Brown et al.
Radiology 2006;239:849-855.
ABSTRACT | FULL TEXT  

Origin and funding of the most frequently cited papers in medicine: database analysis
Patsopoulos et al.
BMJ 2006;332:1061-1064.
ABSTRACT | FULL TEXT  

Ties That Bind: Multiple Relationships Between Clinical Researchers and the Pharmaceutical Industry
Henry et al.
Arch Intern Med 2005;165:2493-2496.
ABSTRACT | FULL TEXT  

Who Is Teaching Psychopharmacology? Who Should Be Teaching Psychopharmacology?
Dubovsky
Acad. Psychiatry 2005;29:155-161.
ABSTRACT | FULL TEXT  

Psychiatry and the pharmaceutical industry: who pays the piper?: A perspective from the Critical Psychiatry Network
Moncrieff et al.
Psychiatr. Bull. 2005;29:84-85.
FULL TEXT  

Inside Information: Financial Conflicts of Interest for Research Subjects in Early Phase Clinical Trials
Helft et al.
JNCI J Natl Cancer Inst 2004;96:656-661.
ABSTRACT | FULL TEXT  

Implementation Of Financial Disclosure Policies To Manage Conflicts Of Interest
Boyd et al.
Health Aff (Millwood) 2004;23:206-214.
ABSTRACT | FULL TEXT  

Industry Funding of Clinical Trials: Benefit or Bias?
Chopra
JAMA 2003;290:113-114.
FULL TEXT  

The Rise of Litigation in Human Subjects Research
Mello et al.
ANN INTERN MED 2003;139:40-45.
ABSTRACT | FULL TEXT  

Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement
Moynihan
BMJ 2003;326:1189-1192.
FULL TEXT  

Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman et al.
JAMA 2003;289:454-465.
ABSTRACT | FULL TEXT  

Research fraud: Why nurses should become aware
Kenkre and Semple
Journal of Research in Nursing 2003;8:47-56.
ABSTRACT  

A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors
Schulman et al.
NEJM 2002;347:1335-1341.
ABSTRACT | FULL TEXT  

Conflicts of Interest in Clinical Research: Addressing the Issue of Physician Remuneration
Caulfield and Griener
J Law Med Ethics 2002;30:305-308.
 

Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign * Commentary: Who pays the guideline writers? * Commentary: Thrombolysis in stroke: it works!
Lenzer et al.
BMJ 2002;324:723-729.
FULL TEXT  

From Clinical Trial to Prescription
Carpenter
Arch Gen Psychiatry 2002;59:282-285.
ABSTRACT | FULL TEXT  

Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry
Choudhry et al.
JAMA 2002;287:612-617.
ABSTRACT | FULL TEXT  

Legal Issues in Scientific Research
Kalb and Koehler
JAMA 2002;287:85-91.
ABSTRACT | FULL TEXT  

Maintaining the integrity of the scientific record
Smith
BMJ 2001;323:588-588.
FULL TEXT  

Dancing with the porcupine: rules for governing the university-industry relationship
Lewis et al.
CMAJ 2001;165:783-785.
FULL TEXT  

Reporting Financial Conflicts of Interest and Relationships Between Investigators and Research Sponsors
DeAngelis et al.
JAMA 2001;286:89-91.
FULL TEXT  

To Protect Those Who Serve
Drazen and Koski
NEJM 2000;343:1643-1645.
FULL TEXT  

In Whose Best Interest? Breaching the Academic-Industrial Wall
Martin and Kasper
NEJM 2000;343:1646-1649.
FULL TEXT  

Conflict of Interest and the Public Trust
DeAngelis
JAMA 2000;284:2237-2238.
FULL TEXT